AI drug discovery is not a “magic wand” — it is a layer technology quietly but durably reshaping operations across the drug discovery value chain. Watching only the headline-grabbing “AI-discovered drug candidates” misses the bigger picture. This hub article consolidates Morning Glory Sciences’ “AI Drug Discovery: Two Layers” series (5 parts) into a single overview, mapping how AI is changing each stage — compound management, preclinical translation, clinical trials, post-market surveillance. Researchers, pharma BD, VCs, and tech-side readers can see the full landscape in one piece.
What This Hub Covers
- The two-layer structure: “headlines” vs. “operational transformation”
- 5-company map (Insitro, Recursion, Schrödinger, BenevolentAI, Atomwise) and current state
- Compound management × AI × robotics — reactivating legacy chemical assets
- Mechanistic modeling × AI bridging the preclinical-to-clinical translation gap
- Digital twins and in silico cohorts reshaping clinical trials (5 turning points)
- AI pharmacovigilance redesigning post-market adverse-event detection
Series Structural Map (5 Vols)
Vol.1 — Reading AI Drug Discovery’s Two Layers: 5-Company Map of Headlines vs. Operational Transformation
Maps the five companies always referenced in AI drug discovery (Insitro, Recursion, Schrödinger, BenevolentAI, Atomwise) along strategy (platform vs. partnership vs. in-house development) and current state (revenue, pipeline, deals). A baseline for separating the “AI drug discovery = revolution” headline from the actual operational shifts underneath. → Read Vol.1
Vol.2 — How Compound Management Reshaped Drug Discovery: 3 Axes of AI × Robotics-Driven Asset Reuse
How AI and automated robotics are reactivating the tens of millions of physical compounds accumulated by large pharma over decades. Three axes — HTS modernization, compound handling, data integration — show how legacy assets become future resources. Case studies from Eli Lilly, Pfizer, and Takeda at the implementation stage. → Read Vol.2
Vol.3 — How Mechanistic Modeling × AI Closes the Preclinical-to-Clinical Gap: 3 Axes of Translation Speed
The highest-failure-rate transition in drug discovery — preclinical-to-clinical translation — is being closed by mechanistic PK/PD modeling × AI. Three axes (precision PBPK, QSP models, virtual patient simulation) materially reduce Phase 1 failure. Includes AstraZeneca and Roche’s latest implementations. → Read Vol.3
Vol.4 — How Virtual Trials Will Reshape Clinical Development: Digital Twins and In Silico Cohorts (5 Turning Points)
AI-based virtual trials (digital twin, in silico cohort, synthetic control arm, external comparator) address trial cost, duration, and recruitment challenges. Five turning points, situated against FDA/EMA regulatory frameworks (CDER/OCE Real-World Evidence guidance, ICH M14, Project Sentinel). → Read Vol.4
Vol.5 (Finale) — The Future of Pharmacovigilance: AI and Machine Learning Reshaping Adverse-Event Detection
How post-market safety surveillance (PV) is being redesigned via AI/ML. Three axes (NLP on medical text, social media sentinel signals, EHR-integrated active surveillance) reshape FDA Sentinel and EMA EudraVigilance frameworks. The series finale that closes the full “AI across the entire drug discovery layer” picture. → Read Vol.5 (finale)
Cross-Cluster Context: Where AI Drug Discovery Connects
- KRAS Frontier series — Revolution Medicines, Eli Lilly, Insitro, and others use AI for compound exploration and resistance prediction; connect to the KRAS competitive map
- From Beginner to Expert: AI in Drug Discovery (7-part complete series + bonus) — modality-by-modality (small molecule, antibody, nucleic acid, cell/gene therapy) AI applications, a definitive primer
- FDA Approval Archive — examples (still few but multiple in 2026) of AI-discovered candidates reaching FDA approval
Strategic Perspective / My Thoughts
Predicting the “next decade” of AI drug discovery is more accurate via operational transformation (how deeply AI has embedded in each drug discovery layer) than via headlines (how many AI-discovered drugs are approved). This series focuses on the former: 5-company map (Vol.1) → compound management (Vol.2) → preclinical-clinical translation (Vol.3) → trial design (Vol.4) → post-market safety (Vol.5), mapping the full drug discovery value chain. Investors gain a realistic AI-company monetization path; pharma BD gains internal-AI investment prioritization; researchers see what AI is changing in their specific domain.
Full Series Links
- Vol.1: Reading AI Drug Discovery’s Two Layers — 5-Company Map of Headlines vs. Operational Transformation
- Vol.2: How Compound Management Reshaped Drug Discovery — 3 Axes of AI × Robotics-Driven Asset Reuse
- Vol.3: How Mechanistic Modeling × AI Closes the Preclinical-to-Clinical Gap — 3 Axes of Translation Speed
- Vol.4: How Virtual Trials Will Reshape Clinical Development — Digital Twins and In Silico Cohorts (5 Turning Points)
- Vol.5 (Finale): The Future of Pharmacovigilance — AI and Machine Learning Reshaping Adverse-Event Detection
※This hub article is the consolidated index for Morning Glory Sciences’ “AI Drug Discovery: Two Layers” series (5 parts). For cases, data, and regulatory context, refer to each Vol.
Comments